Verona Pharma plc (VRNA)

Verona Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	271.77	227.83	148.38	187.99	30.43
Short-Term Investments	0	0	0	0	10.38
Cash & Cash Equivalents	271.77	227.83	148.38	187.99	40.81
Cash Growth	19.29%	53.54%	-21.07%	360.66%	-61.08%
Other Current Assets	17.94	15.17	21.68	14.52	13.49
Total Current Assets	289.71	243	170.06	202.5	54.3
Property, Plant & Equipment	2.87	0.93	0.98	1.16	1.35
Long-Term Investments	15	15	15	0	0
Goodwill and Intangibles	0.55	0.55	0.55	0.55	0.59
Total Long-Term Assets	18.42	16.47	16.52	1.7	1.94
Total Assets	308.12	259.47	186.59	204.21	56.23
Accounts Payable	3.49	2.91	10.04	0.18	1.93
Current Debt	1.18	0.68	0.65	0.8	0.61
Other Current Liabilities	4.02	15.44	22.73	13.23	10.3
Total Current Liabilities	8.69	19.03	33.42	14.2	12.84
Long-Term Debt	50.15	9.97	5.16	5.15	0.65
Total Long-Term Liabilities	50.15	9.97	5.16	5.15	0.65
Total Liabilities	58.84	29	38.58	19.35	13.49
Total Debt	51.33	10.65	5.81	5.95	1.26
Debt Growth	382.05%	83.33%	-2.34%	370.86%	125.51%
Retained Earnings	-388.43	-333.1	-263.72	-207.05	-141.78
Comprehensive Income	-4.6	-4.6	-4.6	-4.6	-2.28
Shareholders' Equity	249.28	230.47	148.01	184.85	42.74
Net Cash / Debt	220.44	217.18	142.57	182.04	39.55
Net Cash / Debt Growth	1.50%	52.33%	-21.68%	360.33%	-62.08%
Net Cash Per Share	0.35	0.41	-	-	-
Working Capital	281.02	223.97	136.64	188.3	41.46
Book Value Per Share	3.15	3.48	2.47	4.29	3.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).